HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging brain

Press Release

Paris, 19 March 2013 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, announces the participation of Hybrigenics Services, its subsidiary specialized in protein interactions, to the kick-off meeting today of the European FP7 research project called "AgedBrainSYSBIO" (http://ec.europa.eu/research/health/medical- research/human-development-and-ageing/projects/agedbrainsysbio_en.html). This project is coordinated by Prof. Michel Simonneau, an expert in functional genomics applied to neurosciences from Sainte-Anne Hospital in Paris.

Hybrigenics Services will perform yeast two-hybrid (Y2H) screens on selected proteins strongly suspected to be involved in late-onset Alzheimer disease (AD), and blow up extensive protein interaction maps around them. This expanded network information will be crossed with data from human genome-wide genetic association studies to validate the relevance of susceptibility genes for AD. Hybrigenics Services will receive €0.6m over four years.

After the Genethon's project on limb-girdle muscular dystrophies (see Hybrigenics' press release of 14 March 2013), AgedBrainSYSBIO represents the second scientific endeavour of similar large scale to which Hybrigenics will contribute with its functional proteomics expertise.

"The concept of matching proteomics and genomics information to pin-point the most relevant gene-protein couples is gaining momentum in the life science community. It is one of the key features of the hot new field called systems biology, in which Hybrigenics Services is naturally settling," said Remi Delansorne, Hybrigenics Services' President.

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE- Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®,

which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is currently being tested in chronic lymphocytic leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by
exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

1/2

Press Release

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.fr

2/2

distributed by